TSX: LOVE | OTCQX: LOVFF | FRA: 8CB0

cannara

PREMIUM-QUALITY CANNABIS AT SCALE

ORCHID CBD

TRIBAL

Nugz

INVESTOR DECK
July 2026

General Disclosures

Disclaimer

This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the Company's most recent Annual Information Form, as well as in the Company's most recent consolidated financial statements, together with the notes thereto and, where applicable, the auditor's report thereon (collectively, the "Financial Statements"), as well as the management's discussion and analysis (the "MD&A") in respect thereof. Copies of all such documents are available under Cannara's SEDAR+ profile on www.sedarplus.ca

Market, Industry and Other Data

Certain information contained herein includes market and industry data that has been obtained from or is based upon estimates derived from third party sources, including industry publications, reports and websites. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance or guarantee as to the accuracy or completeness of included data. Although the data is believed to be reliable, neither the Company nor their agents have independently verified the accuracy, currency or completeness of any of the information from third party sources referred to in this Presentation or ascertained from the underlying economic assumptions relied upon by such sources. The Company and their agents hereby disclaim any responsibility or liability whatsoever in respect of any third-party sources of market and industry data or information.

No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this Presentation, and any representation to the contrary is an offence.

The information contained in this presentation does not purport to be all inclusive or to contain all information that prospective investors may require. Prospective investors are encouraged to conduct their own analysis and reviews of the Company and of the information contained in this presentation. Without limitation, prospective investors should consider the advice of their financial, legal, accounting, tax and other advisors and such other factors they consider appropriate in investigating and analyzing the Company. The Company has not authorized anyone to provide investors with additional or different information. If anyone provides an investor with additional or different or inconsistent information the investor should not rely on it.

Non-GAAP and Other Financial Measures

In this presentation, the following non-GAAP measures, non-GAAP and other supplementary financial ratios are used by the Company: adjusted EBITDA, free cash flow, working capital, segment gross profit before fair value adjustments as a percentage of segment net revenue, segment gross profit as a percentage of segment net revenue, segment operating income as a percentage of segment net revenue, gross profit as a percentage of total revenues and adjusted EBITDA as a percentage of net revenue. Management of the Company ("Management") employs these measures internally to measure operating and financial performance. Management believes that these non-GAAP and other financial measures provide useful information to investors and analysts regarding the Company's financial condition and results of operations as they provide additional key metrics of its performance. These non-GAAP and other financial measures are not recognized under IFRS, do not have any standardized meaning prescribed under IFRS and may differ from similarly named measures as reported by other issuers, and accordingly may not be comparable. These measures should not be viewed as a substitute for the related financial information prepared in accordance with IFRS.

General Disclosures

Forward-Looking Statements

This presentation may contain "forward-looking information" within the meaning of Canadian securities legislation ("forward-looking statements"). These forward-looking statements are made as of the date of this presentation and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect Company management's expectations or beliefs regarding future events and include, but are not limited to, the Company and its operations, its projections or estimates about its future business operations, its planned expansion activities, anticipated product offerings, the adequacy of its financial resources, the ability to adhere to financial and other covenants under lending agreements, future economic performance, and the Company's ability to become a leader in the field of cannabis cultivation, production, and sales.

In certain cases, forward-looking statements can be identified by the use of words such as "plans," "expects" or "does not expect," "is expected," "budget," "scheduled," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases or statements that certain actions, events or results "may," "could," "would," "might" or "will be taken," "occur" or "be achieved" or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including "may," "future," "expected," "intends" and "estimates." By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in, or implied by, such forward-looking information. These risks and uncertainties include, but are not limited to, the following risk factors which are discussed in greater detail under "Risk Factors" in the Company's AIF available on SEDAR+ at www.sedarplus.ca and under the "Investor Area" section of our website at https://www.cannara.ca/en/investor-area: compliance with laws, reliance on licenses, costs associated with numerous laws and regulations, change in laws, regulations, and guidelines, competition, competition from the illicit market, risks related to Canadian excise duty framework, insurance and uninsured or uninsurable risk, key personnel, labour costs, labour shortages, and labour relations, liquidity and future financing, conflicts of interest, litigation risk, intellectual property, IT and security risk, agricultural and cannabis operations, third-party transportation disruptions, commodity price risks, fluctuating prices of raw materials, environmental and employee health and safety regulations, restrictions on promotion and marketing, unfavorable publicity or consumer perception, significant ownership interest of management, directors, and employees, speculative nature of investment, global economy risk, risks related to the ownership of the common shares, forward-looking statements and risks, volatility of common shares market price, non-payment of dividends, future sales of common shares, unlimited issuance of common shares without shareholder approval, fluctuations in operating results, lack of research analyst coverage, limited control by shareholders over operations and risks related to internal controls over financial reporting.

This is not an exhaustive list of risks that may affect the Company's forward-looking statements. Other risks not presently known to the Company or that the Company believes are not significant could also cause actual results to differ materially from those expressed in its forward-looking statements. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, readers are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information. Certain assumptions were made in preparing the forward-looking information concerning the availability of capital resources, business performance, market conditions, as well as customer demand. Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein is provided as of the date hereof, and the Company disclaims any intention to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

Cannara: One **LOVE**

One of Canada's Fastest Growing Top-10 Licensed Producers*. Scalable. Profitable.

Proudly Cannara

450+

Team members
HQ: Montreal, Canada
Grow: Farnham & Valleyfield

3 Flagship Brands

TRIBAL
Nugz
ORCHID CBD

Scaled Capacity

>58,000 KG

Current annualized production with owned high ROI capacity to reach 100,000 kg annually

Retail Presence*

8/10 Provinces

94% Of Retail Stores

3.3% Of Retail Listings

Retail Market Leadership*

#1 LP In Quebec

#8 LP In Canada

Sustained Profitability

21 Consecutive quarters of positive Adjusted EBITDA

15 Consecutive quarters positive operating cash flow

*According to Hifyre, Turff, & Weedcrawler for July 2026

Recent Milestones & Execution Milestones

Overview
Financials
Assets
Strategy
Performance
Fact Sheet
Leadership
Summary

March 2026
Cannara graduates to Toronto Stock Exchange

May 2026
Cannara announces completed acquisition of Medican Organic Inc for an aggregate purchase price of $2.8 million.

July 2026
Cannara secures exclusive Canadian rights to U.S.-based Blue River's Ampersand™ live rosin infusion technology

July 2026
Cannara enters long-term international supply agreement with Curaleaf International, with potential aggregate value of $21M CAD

Our Three Pillars

A repeatable operating system built for profitable growth

Market Discipline

SKU discipline + category focus

Velocity + inventory turns

Cash-first capital allocation

Low-cost Scale

Current >58,000 kg annualized production

$30M CAPEX plan over 3 years to reach 100,000 kg annualized production

Consumer-first Approach

GROWUP

Tribal
2025 Brand of the Year

Nugz Häpple
2025 Accessory of the Year

KING

Tribal Cuban Linx Trifecta
2025 Pre-roll of the Year

Nugz Hash Rosin
2025 Concentrate of the Year

Profitability Sets Us Apart

	Q3 2026	Q3 2025	Variance	Q3 2026 YTD	Q3 2025 YTD	Variance
Gross revenue	**$45.1M**	**$38.8M**	***+$6.3M***	**$126.7M**	**$112.4M**	***+$14.3M***
Gross Cannabis Revenue	$44.1M	$37.8M	*+$6.2M*	$123.7M	$109.5M	*+$14.2M*
Gross Real Estate Revenue	$1.01M	$0.97M	*+$0.04M*	$3.0M	$2.9M	*+$0.1M*
Total revenue	**$31.8M**	**$27.3M**	***+$4.5M***	**$89.1M**	**$79.0M**	***+$10.1M***
Gross profit, before fair value adjustments	**$13.4M**	**$12.1M**	***+$1.4M***	**$38.5M**	**$32.7M**	***+$5.8M***
Gross Margin	**42%**	**44%**	***(2pp)***	**43%**	**41%**	***+2pp***
Adjusted EBITDA[1]	**$8.5M**	**$7.6M**	***$0.9M***	**$23.3M**	**$20.7M**	***+$2.6M***
Adjusted EBITDA[1] Margin	**27%**	**28%**	***(1pp)***	**26%**	**26%**	***0pp***
Net Income	**$4.8M**	**$4.1M**	***+$0.7M***	**$7.5M**	**$9.8M**	***($2.2M)***
Operating Cash Flow	**$5.7M**	**$13.9M**	***($8.2M)***	**$16.6M**	**$17.2M**	***($0.6M)***
Operating Cash Flow Margin	**18%**	**51%**	***(33pp)***	**19%**	**22%**	***(3pp)***
Free Cash Flow[1]	**$1.3M**	**$11.7M**	***($10.4M)***	**$4.3M**	**$12.3M**	***($8.0M)***
Free Cash Flow[1] Margin	**4%**	**43%**	***(39pp)***	**5%**	**16%**	***(11pp)***

[1]Please refer to the "Non-GAAP Measures and Other Financial Measures" section of Cannara's most recent MD&A for corresponding definitions.

Well Capitalized Balance Sheet

Selected Financial Highlights	As at May 31, 2026	As at August 31, 2025	Variance ($)
Cash	$21.8M	$14.4M	$7.4M
Accounts receivable	$18.5M	$14.1M	$4.4M
Biological assets	$6.0M	$6.8M	($0.8M)
Inventory	$49.6M	$44.5M	$5.1M
Working capital[1]	$65.1M	$48.0M	$17.2M
PP&E	$92.8M	$85.7M	$7.2M
Total assets	$194.5M	$168.6M	$25.8M
Total current liabilities	$32.6M	$34.2M	($1.6M)
Total non-current liabilities	$36.1M	$32.2M	$3.8M
Net assets	$125.9M	$102.2M	$23.7M

[1] Working capital is a non-GAAP financial measure. For more details see the Non-GAAP and Other Financial Measures section of this MD&A.

Scaling Sales

Cannabis Revenue Growth Trajectory as Valleyfield Production Scales Up



Two Quebec Based Mega Facilities

Valleyfield: 1M sq. ft., 24 independent grow rooms, each 25,000 sq. ft.

Valleyfield Facility

- Acquired in 2021 for $27M vs build price of $250M
- One of the largest indoor cannabis cultivation facilities in Canada
- 24 independent growing zones, each measuring 25,000 sq. ft.
- 1,033,506 sq. ft. on 3,000,000 sq. ft. of land. Provides ability to expand output capacity to 100,000kg



Each activated zone has been designed to replicate indoor growing conditions eliminating variability and maximizing quality.

- 14 of 24 independent cultivation zones activated, representing annualized production capacity of more than 58,000 kg and over 100,000 plants under cultivation.
- Processing centre expansion remains on track. Phase 1 is expected to be completed by the end of calendar 2026 and is designed to expand post-harvest processing capacity to support 100,000kg annualized production capacity by the end of fiscal 2027.

Two Quebec Based Mega Facilities

Farnham: 605,000 sq. ft., 170, 000 sq. ft. of cannabis operations

Farnham Facility

- 605,000 sq. ft. facility provides 170,000 sq. ft. of cannabis operations.
- 18 indoor grow rooms dedicated to nursery cultivation as well as dedicated post harvest, packaging and cannabis processing rooms.
- Solventless hash lab
- Pre-roll manufacturing centre
- R&D Facility (Pheno-hunting, Tissue Culture and Analytical Testing)
- Capital management: unoccupied space listed to non-cannabis tenants, generates over $3.8M in annual rental revenues

Disciplined Growth & Expansion

Cannara's Estimated Fiscal Year End Production Capacity in kg



	FY2022	FY2023	FY2024	FY2025	FY2026	FY2027	FY2028	FY2029	FY2030
# of Operational Grow Rooms at Valleyfield Asset	**6**	**9**	**10**	**12**	**14**	**18**	**21**	**24**	**24**

Capital Deployment & ROI Guardrails

Phased activation with ROI discipline, aligned to demand

What We Fund

Post-processing (gating item)
Unlocks throughput + quality consistency

Room activations (modular growth)
Existing shell, staged activations

Automation & QA
Sustain consistency at higher volume

How We Pace Growth

Demand-led activations
(not speculative buildout)

2–4 rooms per year target cadence

Maintain quality and SKU discipline as volume increases

ROI Guardrails

Modest incremental capex per room
(activation, not construction)

Target payback within a disciplined window (<12 months)

Protect margins + cash flow while scaling

Funding capacity supported by liquidity + undrawn capex facility

Incremental EBITDA and cash flow growth driven by staged activation, not facility expansion

Canadian Recreational Cannabis Market

Continued year-over-year growth, record R12M retail sales in April 2026 of $5.72B (+4.7%)

Rolling 12-Month Retail Sales of Legal Cannabis Stores in Canada from November 2022 to April 2026



- Cannara continues to gain market share in a growing Canadian cannabis market through product innovation, expanding national distribution and disciplined execution.
- With annualized production now exceeding 58,000 kg and expected to reach approximately 75,000 kg by the end of FY 2027, Cannara is well positioned to continue capturing market share while participating in the industry's long-term growth.

Statistics Canada, Table 20-10-0056-01; NAICS 459993, Cannabis retailers; unadjusted total retail sales

Why Quebec

Quebec has one of the **lowest electricity rates** in Canada
(ex: QC: ~6.6¢/kWh vs. AB: ~13.7¢/kWh)

Quebec has the **highest barriers of entry** resulting in the **lowest number of Licensed Producers** in the market.

Quebec has the **third largest cannabis retail market** (quarterly retail sales) despite being serviced by the fewest number of brands, licensed producers, and retail outlets.

Average Electricity Rates By Province In Cents Per Kw Hour





March '26 To May '26 (Q3 2026) Estimated Cannabis Retail Sales



Hydro Quebec, Electricity Rates
Weedcrawler (https://Quebec.weedcrawler.ca), BCLDB, AGLC, OCS, SQDC, Turff, and Hifyre Database

Competitive Advantage

Scalable Quality

Premium, craft-style quality delivered at scale through controlled 25,000 sq. ft. grow zones and full product transparency.

Price Competitiveness

Value-based pricing enabled by Quebec's low operating costs and a fully integrated, efficient cost structure.

Customer Loyalty

Consistent repeatable experiences with a wide selection of products

Community Engagement

Direct engagement with consumers and retailers that strengthens relationships and fuels product improvement

Innovation & Rare Genetics

Continuous innovation through pheno-hunting and products that fill market gaps

Our brand portfolio is built on a focused strategy: start with the best genetics, run rigorous in-house pheno-hunts, and commercialize only what delivers exceptional quality and consumer value.

TRIBAL

Tribal is Cannara's House of Genetics, built on exclusive genetics, relentless pheno-hunting, and disciplined cultivation to deliver trend-setting premium cannabis at everyday prices

Nugz

Nugz brings top-tier genetics to value-conscious consumers deliver potent, flavourful, and consistent products aligned with leading market trends.

ORCHID CBD

Orchid CBD elevates the wellness category with CBD-rich genetics and full-flower craftsmanship to deliver a refined, terpene-forward experience across flower, pre-rolls, and live resin.

Increasing Our Market Share

Estimated Retail Market Growth[1] ($)

Market	June 2026	Q3 2026	Q2 2026	Q1 2026	FY 2025	FY 2024
National	4.4%	4.4%	4.4%	4.1%	3.8%	2.9%
QC	12.9%	14.1%	14.3%	13.5%	12.7%	8.3%
ON	3.7%	3.5%	3.1%	3.1%	2.8%	2.7%
AB	2.9%	2.6%	2.3%	2.5%	2.5%	1.9%
BC	2.1%	1.7%	2.0%	1.8%	1.6%	1.1%
SK	1.0%	0.9%	1.2%	0.9%	1.0%	1.1%
MB	1.5%	1.6%	1.9%	1.4%	0.8%	0.2%
NS	0.4%	0.5%	0.4%	0.4%	0.5%	0.1%

National Retail Penetration[2]

National Retail Listings	June 2026	Q3 2026	Q3 2025
% Cannara Retail Penetration	3.3%	3.1%	2.5%

June 2026 marked Cannara's highest-ever reported retail market share in Ontario, Canada's largest provincial market, while remaining in #1 in Quebec, Canada's 3rd largest market but retail sales in Q2.

[1]Based on retail market sales dollar, calculated using dataset from Weedcrawler for Quebec retail sales contributions, NSLC for Nova Scotia retail sales, and Hifyre dataset for the rest of Canada.
[1]Turff Analytics, July 2026

A National Revenue Base

54% of Cannara's Canadian Cannabis Retail Sales Outside Québec

Cannara Q3 2026 Revenue by Province



Québec 46% | Ontario 34% | Alberta 11% | British Columbia 6% | MB, SK, NS, NFLD 3%

Brand & Product Portfolio Leadership

Canada's #1 Hash rosin brand (Nugz)	**Canada's #1 Mass premium 3.5g flower brand** (Tribal)	**Canada's #1 Premium Live resin vape brand** (Tribal)	**Canada's #1 CBD flower brand** (Orchid CBD)

Based on retail market sales dollar estimates, Turff Analytics

Executive Leadership Team

Zohar is an entrepreneur who has launched several successful businesses. He has founded, advised and invested in numerous companies including 911ENABLE™ which he led from start-up to its acquisition by West Telecom in 2014. Zohar has been recognized as a top leader and innovator by a number of sources, including Deloitte Technology Fast 50™ fastest growing technology companies in Canada.

ZOHAR KRIVOROT
FOUNDER & CEO

Nicholas Sosiak, CPA, is the dynamic and hands-on executive of Cannara Biotech, passionately shaping the Canadian cannabis industry through a multi-faceted approach. He is deeply involved in all aspects of the company, including finance, accounting, sales, marketing, product development, R&D, and investor relations.

NICHOLAS SOSIAK
COO, Interim CFO

Avi has been in the information technology industry for over 20 years. He specializes in innovation and cutting-edge technologies. Prior to Cannara, Avi has patented 911 software solutions currently being used by many Fortune 500 companies such as Microsoft, Boeing, Disney and the US Department of Defence.

AVI KRIVOROT
CTO

Overview
Financials
Assets
Strategy
Performance
Fact Sheet
Leadership
Summary

ISSAM BEN MOUSSA
VP PRODUCTION & EXPERIMENTATION

NOEMI FOLLAIN
VP FINANCE

BRIAN SHERMAN
VP LEGAL AFFAIRS

FRANCE LANDRY
VP HUMAN RESOURCES

SCOTT CARROLL
VP COMMERCIAL STRATEGY & IR

JUSTIN CONWAY
VP TRANSFORMATION

NICK VAN DAM
VP SALES

ACHRAF AQARI
VP SUPPLY CHAIN

SABRINA SALVO
VP MARKETING

Executive Leadership Team

Overview
Financials
Assets
Strategy
Performance
Fact Sheet
Leadership
Summary

ZOHAR KRIVOROT
CHAIRMAN & CEO

Zohar is a seasoned entrepreneur who has built and grown multiple successful businesses. He has played pivotal roles as a founder, advisor, and investor in numerous ventures, notably 911ENABLE™, which he guided from its inception to its acquisition by West Telecom in 2014. Zohar has earned recognition as a leading innovator and top business leader from various organizations, including Deloitte Technology Fast 50™, which ranks Canada's fastest-growing technology companies. He continues to actively support early-stage businesses as an advisor and board member. Additionally, he is a certified commercial pilot.

DONALD OLDS
LEAD DIRECTOR & CHAIRMAN OF THE AUDIT & GOVERNANCE COMMITTEE

Donald Olds is an experienced life sciences executive, entrepreneur and director with significant experience raising capital for private and public technology companies. Most recently, he was President and Chief Executive Officer of Montreal-based NEOMED Institute, a position he held until the successful closing of a merger with Vancouver-based CDRD.

DEREK STERN
DIRECTOR

Derek is the Vice President of Olymbec. He owns, operates and manages a diverse portfolio of industrial, retail and residential properties across North America. Olymbec is now one of the largest private industrial real estate holders in Eastern Canada.

The Company has experienced an annual growth rate of over 10%. Derek played a key role in the company's rapid growth by strategically acquiring and repositioning vacant properties and marketing them to a new client base.

MARY DUROCHER
DIRECTOR

Mary has been involved in the cannabis industry since the infancy of the Marijuana for Medical Purposes Regulations introduction. Mary serves as President of Fox D Consulting, a regulatory consulting firm focusing on the Canadian cannabis industry and offers a diverse range of consulting services for the cannabis industry in Canada, the United States and the European Union. Mary's board experience and industry contacts has enabled her to create a comprehensive foundation in the fundamentals of regulatory compliance within the cannabis industry worldwide.

JUSTIN COHEN
DIRECTOR

Justin Cohen is a seasoned executive specializing in scaling businesses, optimizing operations, and driving revenue growth across retail, healthcare, and consumer industries. With expertise in multi-channel strategy, digital acceleration, and portfolio integration, he has led high-growth transformations, delivering 10X revenue expansion, streamlining operations, and future-proofing organizations. His leadership blends ambitious strategy with strong execution, ensuring sustainable growth in competitive markets. As a board member and executive advisor, he provides strategic guidance on commercialization, digital transformation, and operational excellence to high-growth and established companies.

Strategy Backed by Results

Premium quality at scale, delivered at disruptive prices, enabled by disciplined execution

	STRATEGY	EXECUTION	RESULTS
LEADERSHIP	**Premium Quality** At-scale	**Vertical Integration** Seed to sale	**#1 in Quebec** Market share leader
PROFITABILITY	**Disruptive Pricing** Structural cost edge	**Operational Excellence** Yields & efficiency	**Profitable Growth** Positive cash flow
GROWTH	**Disciplined Expansion** High ROI capacity	**Community Branding** Pull-through demand	**Clear Scale Runway** Distribution & capacity

Built for **PROFITABLE GROWTH**

TSX: LOVE | OTCQX: LOVFF | FRA: 8CB0

cannara

THANK YOU

www.cannara.ca

investors.cannara.ca

www.instagram.com/cannarabiotech

www.facebook.com/cannarabiotech

CANNARA HEADQUARTERS
333 Decarie blvd, Suite 200
Saint-Laurent, QC, H4N 3M9

FARNHAM FACILITY
1144 Boulevard Magenta E
Farnham, QC, J2N 1C1

VALLEYFIELD FACILITY
1175 Boulevard Gérard-Cadieux
Salaberry-de-Valleyfield, QC, J6T 6L3

CONTACT US
WE WOULD LOVE
TO HEAR FROM YOU

NICHOLAS SOSIAK
COO, Interim CFO
(514) 688 - 0007
nick@cannara.ca

SCOTT CARROLL
VP INVESTOR RELATIONS
(514) 830 - 7325
scott@cannara.ca